Company: INKT
Filing Date: 2025-03-18
Form Type: 10-K
Source: 0000950170-25-041379
Chunk: 124

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-03-18
Form: 10-K
Item: Item 1A
Chunk 124
---
 associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. 

General Risk Factors 

The market price of our common stock may be volatile, which could result in substantial losses for investors. 

Some of the factors that may cause the market price of our common stock to fluctuate include: 

•the success of existing or new competitive product candidates or technologies; 

•the timing and results of preclinical studies or clinical trials for any product candidates that we may develop; 

•failure or discontinuation of any of our product development and research programs; 

•results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; 

•developments or changing views regarding the use of allogeneic cell therapies; 

•commencement or termination of collaborations for our product development and research programs; 

•regulatory or legal developments in the United States and other countries; 

•developments or disputes concerning patent applications, issued patents or other proprietary rights; 

•the recruitment or departure of key personnel; 

•the level of expenses related to any of our research programs, clinical development programs or product candidates that we may develop; 

 59

•the results of our efforts to develop additional product candidates or products; 

•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; 

•announcement or expectation of additional financing efforts; 

•sales of our common stock by us, our insiders or other stockholders; 

•expiration of market stand-off or lock-up agreement; 

•variations in our financial results or those of companies that are perceived to be similar to us; 

•changes in estimates or recommendations by securities analysts, if any, that cover our stock; 

•changes in the structure of healthcare payment systems; 

•market conditions in the pharmaceutical and biotechnology sectors; 

•general economic, industry and market conditions; and 

•the other factors described in this “Risk Factors” section. 

In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company’s securities, securities